Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Strengthening the clinical leadership as the Company progresses to the clinic with its BRD9 Targeted Glue™, AMX-883, in acute myeloid leukemiaAmphista continues to advance its SMARCA and TEAD...
-
Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein...
-
Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein...